Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Dec 22, 2020 4:00pm
235 Views
Post# 32162987

RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"

RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"As SPCEO has pointed out, the market is unfortunately very highly swayed in the very short term by the trading around set algorithms, some, for example, based around things like the silliness of counting the number of positive vs. negative words in a PR announcement, any "new buy" announced (like we saw today), anything having to do with certain types of announcements (like the AACR presentation day when THTX  traded 7mil shares, mostly traded amongst themselves), etc....  I would not expect this "Loe's Bounce" to have legs. It's all noise trading, not investing.  

By the way, this is also why some companies are constantly announcing stuff -- to feed the day traders and algos. It can stay that way until it can't -- until one of the short selling publishers brings some sense to it like Citron did to CYDY.  Unfortunately it can last long enough to create $4bil of value in CYDY based on a drug that so far hasn't shown it can do anything.  

Let's just hope that THTX can have actual legitimate news to disseminate on a regular basis starting around now and going through the year to create the momentum it needs -- financial momentum around revenues/cash flows, share price momentum, pipeline momentum and newsflow momentum.  They need it in all realms!



Jasonthehumble wrote: Your theory might be true due to the high volume compared to the average volume.


<< Previous
Bullboard Posts
Next >>